<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087058</url>
  </required_header>
  <id_info>
    <org_study_id>RLY5016-206p</org_study_id>
    <secondary_id>2016-002785-31</secondary_id>
    <nct_id>NCT03087058</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic &amp; Safety of Patiromer in Children &amp; Adolescents (2-&lt;18 Yrs) With Chronic Kidney Disease and Hyperkalemia</brief_title>
  <acronym>EMERALD</acronym>
  <official_title>A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to &lt; 18 Years of Age With Chronic Kidney Disease and Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relypsa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relypsa, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the change in serum (blood) potassium levels from
      start of treatment to Day 14, when patiromer is administered at different doses, once daily,
      in children 2 - &lt; 18 years of age with chronic kidney disease (CKD) and hyperkalemia (too
      much potassium in the blood). Another purpose of the study is to evaluate the safety and
      tolerability of patiromer in children 2 - &lt; 18 years of age with CKD and hyperkalemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 54 subjects, 2 - &lt; 18 years of age with CKD (estimated glomerular filtration rate
      [eGFR] &lt; 60 mL/min/1.73 m2 ) and hyperkalemia (two potassium measurements of 5.1 to &lt; 6.5
      mEq/L performed on separate days) will be enrolled in this open-label, multiple-dose, Phase 2
      study. The study will include two treatment phases: Pharmacodynamic (PD; drug effect on
      potassium) / Dose Finding Phase consisting of the initial 14-day dose finding period followed
      by an up to 5.5-month Long-Term Treatment Phase for a total study participation duration for
      individual subjects of up to 6.5 months (includes a 2 week follow up period).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum potassium levels from Baseline to Day 14</measure>
    <time_frame>Baseline and Day 14</time_frame>
    <description>Changes in serum potassium levels will be summarized by starting dose and age group using descriptive statistics. Descriptive statistics include mean, standard deviation, and 95% confidence intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L at Day 14 (Initial PD / Dose Finding Phase)</measure>
    <time_frame>Day 14</time_frame>
    <description>Proportions and associated exact 95% confidence interval will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with serum K+ levels in the range of 3.8 - 5.0 mEq/L by visit at any time through Month 6 (Long-Term Treatment Phase)</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>Proportions and associated 95% confidence interval will be presented.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiromer for age 12 ‒ &lt; 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiromer for age 6 ‒ &lt; 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patiromer for age 2 ‒ &lt; 6 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>4.2 g/day, 8.4 g/day and 16.8 g/day</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Veltassa</other_name>
    <other_name>RLY5016 for Oral Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>2 g/day, 4 g/day and 8 g/day</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Veltassa</other_name>
    <other_name>RLY5016 for Oral Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer</intervention_name>
    <description>1 g/day, 2 g/day and 4 g/day</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Veltassa</other_name>
    <other_name>RLY5016 for Oral Suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written assent (when applicable) and written informed consent by a legally authorized
             representative provided prior to participation in the study

          -  Age 2 - &lt;18 years old

          -  CKD defined by eGFR &lt;60 mL/min/1.73m2 including renal transplant, peritoneal dialysis

          -  Two potassium measurements of 5.1 to &lt; 6.5 mEq/L performed on separate days

          -  In the opinion of the study doctor, is expected to require treatment for hyperkalemia
             for at least 6 months

          -  If taking any renin-angiotensin-aldosterone system inhibitors (RAASi) beta blockers or
             diuretic medications, must be on a stable dose for at least 28 days prior to Screening

          -  Negative pregnancy test in females of child-bearing potential

        Exclusion Criteria:

          -  False elevation in blood potassium (pseudohyperkalemia) due to hemolysis (breaking of
             blood cells) or abnormally high counts of blood cells at Screening

          -  Evidence of potassium-related electrocardiogram (ECG) changes at Screening

          -  Any of the following kidney conditions: hemodialysis, renal artery stenosis, and acute
             kidney injury or a history of acute renal insufficiency in the past 3 months

          -  Severe disorder of stomach or intestines including surgery

          -  Increased liver enzymes (ALT, AST &gt; 3 times upper limit of normal) at Screening

          -  Active cancer, currently on cancer treatment or history of cancer in the past 2 years
             (except for non-melanoma skin cancer)

          -  Have had a heart or liver transplant, or anticipated need for transplant during the
             study treatment period including a scheduled kidney transplant. (Note: patients
             currently on a kidney transplant wait list are not excluded unless there is an
             identified donor).

          -  Alcohol abuse or substance use disorder within 1 year of Screening

          -  Subjects currently being treated with or having taken any one of the following
             medications (includes resins) in the 7 days prior to Screening: sodium or calcium
             polystyrene sulfonate, drospirenone

          -  Use of certain medications that can affect blood potassium levels if doses have not
             been stable for at least 14 days prior to Screening or if doses are anticipated to
             change during the 14-day PD / Dose Finding Phase

          -  Use of investigational product within 30 days of screening or within 5 half-lives,
             whichever is longer

          -  Known hypersensitivity to patiromer or its components

          -  In the opinion of the Investigator, any medical condition, uncontrolled systemic
             disease, or serious intercurrent illness that would significantly decrease study
             compliance or jeopardize the safety of the subject or potentially affect the quality
             of the data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director or VP Clinical Development</last_name>
    <role>Study Director</role>
    <affiliation>Relypsa, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Head of Clinical Operations</last_name>
    <phone>650-421-9500</phone>
    <email>emerald@relypsa.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 1111</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1108</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>84305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1110</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1101</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1103</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1112</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1102</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1105</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1107</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1104</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>77106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1109</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1113</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1106</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1401</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1901</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>T3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3915</name>
      <address>
        <city>Tbilisi</city>
        <zip>0121</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3913</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3911</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3912</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3914</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4312</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4313</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4311</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investiagor Site 4314</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5401</name>
      <address>
        <city>Bialystok</city>
        <zip>15-001</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5404</name>
      <address>
        <city>Gdansk</city>
        <zip>80-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5406</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5402</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5403</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5405</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7502</name>
      <address>
        <city>Mayville</city>
        <zip>4058</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7501</name>
      <address>
        <city>Pretoria</city>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7906</name>
      <address>
        <city>Dnipro</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7903</name>
      <address>
        <city>Kharkiv</city>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7901</name>
      <address>
        <city>Kharkiv</city>
        <zip>61093</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7904</name>
      <address>
        <city>Kyiv</city>
        <zip>01103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7902</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site 7905</name>
      <address>
        <city>Odessa</city>
        <zip>65038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of Hyperkalemia</keyword>
  <keyword>Hyperkalemia</keyword>
  <keyword>Potassium</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

